Filtered By:
Condition: Ischemic Stroke
Therapy: Statin Therapy
Countries: China Health

This page shows you your search results in order of date.

Order by Relevance | Date

Total 42 results found since Jan 2013.

CYP2C19 Loss-of-Function Variants Associated with Long-term Ischemic Stroke Events During Clopidogrel Treatment in the Chinese Population
This study aims to determine whether CYP2C19 loss-of-function (LoF) variants were associated with long-term ischemic stroke risk in Chinese primary care patients treated with clopidogrel. Patients treated with clopidogrel were ascertained from a Chinese Electronic Medical Record linked with biobank for a retrospective cohort study. Their medical information was examined for the period from January 2018 to December 2021. Two CYP2C19 major loss of function variants (*2:rs4244285, *3: rs4986893) were genotyped. The clinical outcome was ischemic stroke event. Cox regression analysis was used to evaluate the association between...
Source: Clinical Pharmacology and Therapeutics - August 22, 2023 Category: Drugs & Pharmacology Authors: Peng Wu Ziqing Liu Zijian Tian Benrui Wu Jian Shao Qian Li Zhaoxu Geng Ying Pan Ke Lu Qiang Wang Tao Xu Kaixin Zhou Source Type: research

Increased Serum EphrinA1 Is Associated With Parenchymal Hematoma (PH) After Ischemic Stroke
Conclusion Higher serum EphrinA1 is independently associated with higher risk of PH after ischemic stroke. Future studies with larger sa mple size are needed to validate our findings and elucidate the potential role of EphrinA1 in PH.
Source: Cerebrovascular Diseases - April 27, 2023 Category: Neurology Source Type: research

Evaluation and subgroup analysis of the efficacy and safety of intensive rosuvastatin therapy combined with dual antiplatelet therapy in patients with acute ischemic stroke
ConclusionsWithout increasing bleeding and statin-associated adverse events, intensive rosuvastatin therapy plus 7-day DAPT significantly reduced the risk of recurrent stroke, especially for subgroups with high-risk factors.Clinical trial registration. China Clinical Trial Registration Center (ChiCTR1800017809).
Source: European Journal of Clinical Pharmacology - March 1, 2023 Category: Drugs & Pharmacology Source Type: research

A multicenter, prospective, randomized controlled trial of intracranial hemorrhage risk of intensive statin therapy in patients with acute ischemic stroke combined with cerebral microbleeds (CHRISTMAS): Study protocol
This study will shed light on new clinical decisions regarding the long-term serum lipid management in these patients with dilemma in clinical practice.Clinical trial registrationClinicaltrials.gov, identifier: NCT05589454.
Source: Frontiers in Neurology - February 9, 2023 Category: Neurology Source Type: research

Evaluation and subgroup analysis of the efficacy and safety of intensive rosuvastatin therapy combined with dual antiplatelet therapy in patients with acute ischemic stroke
ConclusionsWithout increasing bleeding and statin-associated adverse events, intensive rosuvastatin therapy plus 7-day DAPT significantly reduced the risk of recurrent stroke, especially for subgroups with high-risk factors.Clinical trial registration. China Clinical Trial Registration Center (ChiCTR1800017809).
Source: European Journal of Clinical Pharmacology - December 29, 2022 Category: Drugs & Pharmacology Source Type: research

Projected Impact of Treatment Intensification with Satin, Ezetimibe, and Statin plus Ezetimibe Fixed-Dose Combination on MACE Across Six Countries
CONCLUSION: The 2019 ESC/EAS guideline-based treatment intensification with strategies based on statin, ezetimibe, and statin plus ezetimibe FDC is estimated to result in a substantial population-level benefit in terms of MACE averted compared to BAU.PMID:36134461 | DOI:10.1093/eurjpc/zwac214
Source: Atherosclerosis - September 22, 2022 Category: Cardiology Authors: Michel Farnier Raul D Santos Juan Cosin-Sales Marat V Ezhov Jian Liu Denis Granados Serena Santoni Irfan Khan Alberico L Catapano Source Type: research

Early Initiation of Evolocumab Treatment in Chinese Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
This study aimed to evaluate the efficacy and safety of the early initiation of evolocumab in Chinese patients with ACS undergoing PCI.METHODS: This retrospective cohort study involved 1564 consecutive patients who had been hospitalized with ACS and underwent PCI, and who had elevated LDL-C levels (≥1.8 mmol/L after receiving high-intensity statin therapy for ≥4 weeks; ≥2.3 mmol/L after receiving low- or moderate-intensity statin; or ≥3.2 mmol/L without statin therapy). Patients who received evolocumab (initiated in-hospital and after 18 months) were included in the evolocumab group (n = 414), and all other patient...
Source: Clinical Therapeutics - May 17, 2022 Category: Drugs & Pharmacology Authors: Yahao Zhang Yanghui Zhang Bin Zhang Zheng Chen Yongjie Wei Penglei Chen Chao Chang Guizhi Liu Kui Chen Jiandong Ding Zhengming Jiang Source Type: research

Nontraditional Risk Factors for Residual Recurrence Risk in Patients with Ischemic Stroke of Different Etiologies
Conclusions: LAA and SAO subtypes own the specific nontraditional risk factors while inflammation is a common risk factor for residual recurrence risk of both.Cerebrovasc Dis
Source: Cerebrovascular Diseases - April 7, 2022 Category: Neurology Source Type: research

Standard-Dose Atorvastatin Treatment in Patients With Symptomatic Middle Cerebral Artery Atherosclerotic Stenosis: A Vessel Wall Magnetic Resonance Imaging Study
Conclusion: Vessel wall magnetic resonance imaging could accurately characterize changes in MCA plaques after lipid-lowering therapy. Standard-dose atorvastatin treatment could stabilize and reverse plaques in northern Chinese patients with SMAS.
Source: Frontiers in Neurology - December 8, 2021 Category: Neurology Source Type: research

Statin Treatment in the Acute Phase and the Risk of Post-stroke Pneumonia: A Retrospective Cohort Study
Conclusions: There appeared to be no additional benefits of statin treatment in the acute phase for post-stroke pneumonia reduction among AIS patients.Clinical Trial Registration:http://www.chictr.org.cn, identifier: ChiCTR2000032838.
Source: Frontiers in Neurology - September 6, 2021 Category: Neurology Source Type: research